ES2182914T3 - Inmunopotenciacion inducida de quitosan. - Google Patents

Inmunopotenciacion inducida de quitosan.

Info

Publication number
ES2182914T3
ES2182914T3 ES95934516T ES95934516T ES2182914T3 ES 2182914 T3 ES2182914 T3 ES 2182914T3 ES 95934516 T ES95934516 T ES 95934516T ES 95934516 T ES95934516 T ES 95934516T ES 2182914 T3 ES2182914 T3 ES 2182914T3
Authority
ES
Spain
Prior art keywords
quitosan
immunopotentiation
induced
compositions
induced immunopotentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934516T
Other languages
English (en)
Inventor
Joseph S Podolski
Kuang Hsu
Balbir Bhogal
Gurpreet Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Application granted granted Critical
Publication of ES2182914T3 publication Critical patent/ES2182914T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE MUESTRAN METODOS Y COMPOSICIONES PARA LA POTENCIACION DE UNA RESPUESTA INMUNE QUE INCORPORAN QUITOSANO COMO ADYUVANTE DE INMUNOPOTENCIACION. LA ADMINISTRACION DE LAS COMPOSICIONES DE LA INVENCION SE EFECTUA POR VARIAS VIAS.
ES95934516T 1994-09-23 1995-09-25 Inmunopotenciacion inducida de quitosan. Expired - Lifetime ES2182914T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31153294A 1994-09-23 1994-09-23

Publications (1)

Publication Number Publication Date
ES2182914T3 true ES2182914T3 (es) 2003-03-16

Family

ID=23207335

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95934516T Expired - Lifetime ES2182914T3 (es) 1994-09-23 1995-09-25 Inmunopotenciacion inducida de quitosan.

Country Status (10)

Country Link
EP (1) EP0789590B1 (es)
JP (1) JP3365635B2 (es)
AT (1) ATE223235T1 (es)
AU (1) AU688603B2 (es)
CA (1) CA2200550A1 (es)
DE (1) DE69528074T2 (es)
DK (1) DK0789590T3 (es)
ES (1) ES2182914T3 (es)
PT (1) PT789590E (es)
WO (1) WO1996009805A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
EP1011730A2 (en) * 1996-10-07 2000-06-28 Edge Biosystems, Inc. Targeted addition of soluble polymers to recombinant proteins
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU771525B2 (en) * 1997-03-25 2004-03-25 Zonagen, Inc. Chitosan induced immunopotentiation
CA2255867C (en) * 1997-03-25 2008-02-05 Zonagen, Inc. Chitosan induced immunopotentiation
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6280742B1 (en) * 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
WO2000015253A1 (en) * 1998-09-17 2000-03-23 Zonagen, Inc. Human chorionic gonadotropin vaccines
AU3879200A (en) * 1999-08-16 2001-03-13 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
KR100801123B1 (ko) 2000-08-17 2008-02-05 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
ITMI20010347A1 (it) 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
EP1356826A1 (en) * 2002-04-22 2003-10-29 BIOMAY Produktions- und Handels- Aktiengesellschaft Microparticles comprising carbohydrate beads covalently linked with allergen
JP2009508852A (ja) * 2006-01-23 2009-03-05 クワンジュ インスティチュート オブ サイエンス アンド テクノロジー 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲート及びこれを用いた薬理活性物質の経粘膜運搬方法
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP3006047B1 (en) * 2013-06-06 2019-08-07 Toppan Printing Co., Ltd. Needle body

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
JPH0747546B2 (ja) * 1985-09-11 1995-05-24 イハラケミカル工業株式会社 アジユバント又は免疫増強剤
US4935147A (en) * 1985-12-20 1990-06-19 Syntex (U.S.A.) Inc. Particle separation method
JP2594123B2 (ja) * 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
JP2975632B2 (ja) * 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
JP3150991B2 (ja) * 1991-04-10 2001-03-26 協和醗酵工業株式会社 ハイブリドーマの製造法
JP3263857B2 (ja) * 1992-04-16 2002-03-11 太陽化学株式会社 抗体産生組成物および抗体産生法
CA2153391C (en) * 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses

Also Published As

Publication number Publication date
EP0789590B1 (en) 2002-09-04
WO1996009805A2 (en) 1996-04-04
AU688603B2 (en) 1998-03-12
CA2200550A1 (en) 1996-04-04
JP2001509774A (ja) 2001-07-24
PT789590E (pt) 2002-12-31
DK0789590T3 (da) 2002-11-04
AU3683095A (en) 1996-04-19
DE69528074T2 (de) 2003-04-30
ATE223235T1 (de) 2002-09-15
WO1996009805A3 (en) 1996-07-25
DE69528074D1 (de) 2002-10-10
JP3365635B2 (ja) 2003-01-14
EP0789590A2 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
HU9203871D0 (en) Pharmaceutical application of certain cistine derivatives
ATE203519T1 (de) Chinolinderivate als antimalariamittel
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
NO911065L (no) Fremgangsmaate for fremstilling av lipopeptidderivater.
ATE207076T1 (de) Ara-c derivate
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
IT1270618B (it) Proteine ad attivita' antitumorale
FI892222A (fi) Peptidalkoholer med antikoagulantverkan.
IT9019323A0 (it) Procedimento di preparazione di l-a-glicerilfosforil-d-myoinositolo e suoi sali da fosfatidi grezzi o parzialmente purificati
CA2255867A1 (en) Chitosan induced immunopotentiation
DK0977871T3 (da) Neurotrypsin
EP1131338A4 (en) PROCESS FOR PRODUCING HIGHLY PURIFIED INVASINATED PROTEIN AND USE OF SUCH PROTEIN
WO2001035994A3 (en) Chitosan induced immunopotentiation
ATE223427T1 (de) Modifizierte kojibioside analoge
IL101540A0 (en) Method and composition for the treatment of herpes related disorders
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
MX9202293A (es) Composicion de vacuna no-irritante.